Elironrasib is an orally active and covalent inhibitor of KRASG12C(ON). Elironrasib forms a tri-complex within tumor cells between KRASG12C(ON) and cyclophilin A (CypA). Thus, Elironrasib prevents KRASG12C(ON) from signaling via steric blockade of RAS effector binding. Elironrasib inhibits ERK signaling and induced apoptosis in KRASG12C-mutant H358 cells. Elironrasib also inhibits the proliferation of KRASG12C mutant cells with a median IC50 of 0.11 nM[1][2].
Molecular Weight:
1012.26
Purity:
99.65
CAS Number:
[2641998-63-0]
Formula:
C55H78FN9O8
Target:
Apoptosis,ERK,Ras
Application Notes:
Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
